News | April 28, 2014

JenaValve Expands Series C Venture Financing Round, Appoints New Director and Board Observer

April 28, 2014 — JenaValve Technology Inc. – a privately held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems – announced it has secured an expansion to its Series C venture round of $10 million, increasing the total amount raised in the round from $62.5 million to $72.5 million.

New investors participating in the expansion of the round are U.K.-based Valiance Asset Management and Belgium-based RMM. Current investors participating in the financing round include Edmond de Rothschild Investment Partners; Atlas Venture Fund; NeoMed Management; VI Partners AG; Sunstone Capital A/S; Gimv (GIMB.EN), a publicly traded investment company; Legend Capital and Omega Funds.

The company also announced the addition of a new director and a board observer in conjunction with the financing round. Industry veteran Jan Keltjen was appointed to the JenaValve board of directors, effective Dec. 30, 2013. In addition, life sciences entrepreneur and financier Rudi Mariën was appointed as an observer to the board.

“JenaValve continues to build momentum in the European TAVI market with our novel transapical TAVI system,” said Helmut J. Straubiger, CEO of JenaValve Technology. “As we continue to work to gain clinical experience with our transfemoral TAVI system and build out international regulatory and commercial programs, we welcome the participation of new world-class investors and the governance and experience of Mr. Keltjens and Mr. Mariën as director and board observer, respectively.”

Mr. Keltjens is the chairman and CEO of Steering Brain Stimulation (Sapiens), a medical device company pioneering brain stimulation products. He has a strong track record in the medical device sector and more than 30 years of management experience, including the role of president and CEO of Endosense SA, which was acquired by St. Jude Medical in August 2013.

Mr. Mariën was co-founder, reference shareholder and chairman of Innogenetics, and has been the founder, shareholder and managing director of several clinical reference laboratories. Currently, he is managing director of Barc NV, an international centralized clinical laboratory exclusively dedicated to pharmaceutical studies.

For more information: www.jenavalve.com

Related Content

The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di